When she put cancer back on the front burner last year, GlaxoSmithKline CEO Emma Walmsley gave the company a big task. After all, her predecessor had traded away most of GSK's oncology assets to Novartis.
When she put cancer back on the front burner last year, GlaxoSmithKline CEO Emma Walmsley gave the company a big task. After all, her predecessor had traded away most of GSK's oncology assets to Novartis.